Charles R Cantor

US Patent:

6368813, Apr 9, 2002

Filed:

Mar 23, 2000

Appl. No.:

09/381430

Inventors:

Gabriel O. Reznik - Boston MA
Takeshi Sano - Needham MA
Sandor Vajda - Medfield MA
Cassandra Smith - Boston MA
Charles Cantor - Del Mar CA

Assignee:

The Trustees of Boston University - Boston MA

International Classification:

G01N 3353

US Classification:

435 75, 435 71, 435 691, 530350, 530300, 536 237, 536 231

Abstract:

Compounds and methods are described for producing streptavidin mutants with changed affinities. In particular, modifications to the sequence of the natural streptavidin gene is described to create amino acid substitutions resulting in greater affinity for biotin substitutes than for biotin.

US Patent:

6660229, Dec 9, 2003

Filed:

Jun 13, 2001

Appl. No.:

09/880988

Inventors:

Charles R. Cantor - Del Mar CA
Fouad A. Siddiqi - Boston MA

Assignee:

The Trustees of Boston University - Boston MA

International Classification:

B32B 2704

US Classification:

422 71, 422 70, 422 78, 422 681, 422 80, 422116, 436 59, 436155, 436161

Abstract:

Methods and kits that use nucleotide analogs to confer increased accuracy and improved resolution in the analysis and sequencing of oligonucleotide mixtures are provided.

US Patent:

6869765, Mar 22, 2005

Filed:

Nov 13, 2001

Appl. No.:

09/993346

Inventors:

Cynthia A. Edwards - Menlo Park CA, US
Charles R. Cantor - Del Mar CA, US
Beth M. Andrews - Maynard MA, US
Lisa M. Turin - Redwood City CA, US
Kirk E. Fry - Palo Alto CA, US

Assignee:

Genelabs Technologies, Inc. - Redwood City CA

International Classification:

C12Q001/68

US Classification:

435 6, 435 4, 435 71

Abstract:

The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

US Patent:

7390672, Jun 24, 2008

Filed:

Jun 18, 2007

Appl. No.:

11/764711

Inventors:

Daniel P. Little - Patton PA, US
Charles R. Cantor - Del Mar CA, US
Hubert Köster - La Jolla CA, US

Assignee:

Sequenom, Inc. - San Diego CA

International Classification:

G01N 24/00

US Classification:

436173, 143180, 259287

Abstract:

Provided herein are substrates for matrix-assisted laser-desorption ionization (MALDI) mass spectrometric analysis. Each spot includes 3-hydroxypicolinic acid matrix and no analyte.

US Patent:

7432342, Oct 7, 2008

Filed:

May 1, 2003

Appl. No.:

10/428254

Inventors:

Andreas Braun - San Diego CA, US
Charles R. Cantor - Del Mar CA, US
Stefan M. Kammerer - San Diego CA, US
Susan Taylor - Del Mar CA, US
Charles Cook - Mendham NJ, US
Gary Olson - Moutainside NJ, US
Christopher Self - West Caldwell NJ, US

Assignee:

Sequenom, Inc. - San Diego CA
The Regents of the University of Califonia - Oakland CA

International Classification:

C07K 7/08
C07K 14/00

US Classification:

530324, 530325, 530326

Abstract:

A-kinase anchor protein (AKAPs) muteins, peptides thereof, and nucleic acids encoding the peptides are provided herein. Also provided are transgenic animals, cells comprising transgenes and various methods employing such peptides.

US Patent:

7470517, Dec 30, 2008

Filed:

Apr 8, 2005

Appl. No.:

11/547765

Inventors:

Charles R. Cantor - Del Mar CA, US
Fouad A. Siddiqi - Boston MA, US

Assignee:

Trustees of Boston University - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known sequences. The identities of these sequences are determined solely by the specific fragmentation method used, and are always independent of the target. PSBF can be implemented using electrophoresis, mass spectrometry or any other method that can be used to distinguish the size of the cut nucleic acid sequence fragments.

US Patent:

7569341, Aug 4, 2009

Filed:

Nov 7, 1997

Appl. No.:

08/967269

Inventors:

Christof M. Niemeyer - Bremen, DE
Charles R. Cantor - Del Mar CA, US
Takeshi Sano - Boston MA, US
Cassandra L. Smith - Boston MA, US

Assignee:

Trustees of Boston University - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.

US Patent:

7645576, Jan 12, 2010

Filed:

Mar 17, 2006

Appl. No.:

11/384128

Inventors:

Yuk-Ming Dennis Lo - Kowloon, HK
Rossa Wai Kwun Chiu - Tai Po, HK
Bo Yin Tsui - Kowloon, HK
Chunming Ding - Shatin, HK
Charles Cantor - Del Mar CA, US

Assignee:

The Chinese University of Hong Kong - Shantin, N.T.

International Classification:

C07H 21/04
C12Q 1/68

US Classification:

435 6, 435 911, 435 912, 536 231, 536 243

Abstract:

The non-invasive detection of fetal chromosomal aneuploidies is demonstrated. Alleles of fetal RNA-SNPs present in a biological sample (e. g. maternal blood) containing fetal RNA are detected and quantified in order to determine the ratio of the alleles. This ratio is compared to a standard control consisting of euploid fetuses. Deviation of allele ratio indicates the presence of chromosomal aneuploidy.